Can a new opioid combo make gastroscopy safer for obese patients?

NCT ID NCT07759778

Not yet recruiting Disease control Sponsor: Lu Yi Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial investigates whether combining oliceridine, a newer opioid, with propofol can provide safe and effective sedation for obese patients undergoing a painless gastroscopy. The study aims to determine the optimal dose of propofol when used with oliceridine, potentially reducing breathing problems that standard sedatives can cause. Obese adults (BMI 28 or higher) scheduled for routine gastroscopy will receive the medication combo, with careful monitoring of vital signs and sedation depth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Oliceridine combined with propofol
What this could lead to: If successful, this could establish a safer sedation approach for obese patients undergoing gastroscopy, reducing breathing complications.
What could go wrong: This is a small, early-phase dose-finding study, so results may not apply broadly. There is still a risk of respiratory depression or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL ENDOSCOPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL ENDOSCOPY OBESITY

More trials for these conditions

Other studies related to the condition(s) this trial covers.